3-乙基-戊酸 | 58888-87-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-乙基-戊酸
• 英文名称: 3-ethylpentanoic acid
• 英文别名: 3-ethyl-pentanoic acid；3-ethyl-valeric acid；3-Aethyl-valeriansaeure；2-ethylbutanecarboxylic acid；3-Ethyl-pentancarbonsaeure；3-Ethyl-pentan-saeure
• CAS: 58888-87-2
• 化学式: C₇H₁₄O₂
• mdl: MFCD01709232
• 分子量: 130.187
• InChiKey: ATUUSOSLBXVJKL-UHFFFAOYSA-N

物化性质

• 沸点：
  210.1°C (estimate)
• 密度：
  0.9221 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P271,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P403+P233,P405,P501
• 危险品运输编号：
  3265
• 危险性描述：
  H335,H314

反应信息

• 作为反应物：
  描述：

  3-乙基-戊酸 在 三氯化磷 作用下， 生成 2-Ethylpentanoylchlorid
  参考文献：
  名称：

  Rasetti, Bulletin de la Societe Chimique de France, 1905, vol. <3>33, p. 691

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(2-甲基丁基)丙二酸 生成 3-乙基-戊酸
  参考文献：
  名称：

  Fichter; Kiefer; Bernoulli, Chemische Berichte, 1909, vol. 42, p. 4712

  摘要：

  DOI：

文献信息

• TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE
  申请人：Bristol-Myers Squibb Company

  公开号：US20160130299A1

  公开（公告）日：2016-05-12

  Tubulysin analogs of the formula (I) where R 1 , R 2 R 3 , R 4 , R 5 , R 6 , R 7 , and Y are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.

  管素类似物公式(I)，其中R1、R2、R3、R4、R5、R6、R7和Y如本文所述定义，是一种抗有丝分裂剂，可用于癌症治疗，特别是在与靶向部分结合时。
• [EN] SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE MORPHOLINE ET DE THIOMORPHOLINE SUBSTITUÉS
  申请人：LUNDBECK & CO AS H

  公开号：WO2005087754A1

  公开（公告）日：2005-09-22

  The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

  本发明涉及一般式I的吗啉和硫代吗啉衍生物或其药用盐及其用途。
• [EN] SERINE/THREONINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE SÉRINE/THRÉONINE KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2015103137A1

  公开（公告）日：2015-07-09

  Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.

  提供具有公式I的化合物或其立体异构体、互变异构体或药用可接受盐，这些化合物用于治疗疾病。公开了使用公式I的化合物或其立体异构体、互变异构体或药用可接受盐，用于体外、原位和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• AMINO ACID COMPOUNDS AND METHODS OF USE
  申请人：Pliant Therapeutics, Inc.

  公开号：US20200109141A1

  公开（公告）日：2020-04-09

  The invention relates to compounds of formula (I): or a salt thereof, wherein R 1 , G, L 1 , L 2 , L 3 , and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ 1 integrin and αvβ 6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  本发明涉及如下公式(I)的化合物： 或其盐，其中R1、G、L1、L2、L3和Y如本文所述。公式(I)的化合物及其药物组合物是αvβ1整合素和/或αvβ6整合素的一种或两种的抑制剂，用于治疗纤维化，如非酒精性脂肪肝炎（NASH）、特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• [EN] 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS<br/>[FR] DÉRIVÉS DE 1-HÉTÉROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE ET LEURS UTILISATIONS À TITRE DE MODULATEURS DE PDE9A
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009121919A1

  公开（公告）日：2009-10-08

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with Hc is a mono-, bi- or tricyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of -S(O)r - with r being 0, 1 or 2, and - said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and - said heterocyclyl group is bound to the scaffold by said 1 non- aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.

  该发明涉及新型1,6-二取代吡唑吡嘧啶酮，化学式（I），其中Hc是一个单环、双环或三环杂环基团，其环成员为碳原子和至少1个，优选1个、2个或3个来自氮、氧和硫的杂原子，其以-S(O)r-的形式存在，其中r为0、1或2，所述杂环基团是或包括1个非芳香、饱和或部分不饱和的单环环，其中至少包含1个杂原子作为环成员，所述杂环基团通过所述至少包含1个杂原子作为环成员的非芳香、饱和或部分不饱和的单环环与支架相结合。根据该发明的一个方面，新化合物用于制造药物，特别是用于治疗感知、注意力、学习或记忆缺陷相关疾病的药物。新化合物还用于制造治疗阿尔茨海默病的药物。